Cassava Sciences | PTIE - Ebit


Cassava Sciences reported $-11.86M in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
Abbott USD 2.54B 358M Dec/2025
Amgen USD 3.96B 464M Dec/2025
Biogen USD 659.6M 157M Sep/2025
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Cassava Sciences USD -11.86M 33.53M Sep/2025
Eisai JPY 20.03B 6.36B Dec/2025
Eli Lilly USD 8.99B 1.57B Dec/2025
Geron USD -10.79M 3.1M Dec/2025
J&J USD 5.11B 2.3B Dec/2025
Merck USD 6.24B 1.32B Dec/2025
Novartis USD -9.19B 13.87B Jun/2025
Novavax USD 20.94M 100.32M Dec/2025
Pfizer USD 4.65B 71M Dec/2025
Roche Holding CHF 9.56B 2.1B Dec/2025